Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 39,600 shares, a decline of 43.8% from the February 28th total of 70,400 shares. Based on an average daily volume of 62,300 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.4% of the shares of the stock are short sold.

Institutional Investors Weigh In On Senti Biosciences

An institutional investor recently bought a new position in Senti Biosciences stock. Virtu Financial LLC bought a new position in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 13,356 shares of the company’s stock, valued at approximately $47,000. Virtu Financial LLC owned about 0.28% of Senti Biosciences at the end of the most recent quarter. 25.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Chardan Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Senti Biosciences in a report on Monday, December 2nd.

Senti Biosciences Trading Down 6.2 %

Shares of NASDAQ:SNTI opened at $3.33 on Friday. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The stock has a market capitalization of $16.08 million, a P/E ratio of -0.21 and a beta of 2.52. The business has a 50-day moving average price of $3.90 and a two-hundred day moving average price of $3.47.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($3.13) by $2.46. The business had revenue of $5.86 million during the quarter, compared to analyst estimates of $2.80 million. As a group, equities analysts predict that Senti Biosciences will post -14.54 EPS for the current year.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.